Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” ...

A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of ...

Suneel Kamath, MD, knows too well the sense of helplessness that comes with living through what he calls “the doughnut hole.” ...

KRAS was long thought undruggable in cancer until scientists discovered a hidden binding pocket in mutant KRAS, leading to ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Results show a landmark change that could double survival rates in one of the most difficult oncology diagnoses, but there are still obstacles to overcome.

Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST)- Pivotal data from Phase 3 PEAK ...

Pelareorep combined with FOLFIRI and bevacizumab produced a 19.5-month median duration of response and 33% ORR in second-line ...

FDA granted rapid expanded access for daraxonrasib in previously treated metastatic PDAC, reflecting urgency and a ...

Erasca's share price nosedived 53% after a patient died in its Phase I trial of ERAS-0015, and rival Revolution Medicine ...

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and ...

Every single type of cancer, explained A cancer diagnosis can be both terrifying and confusing for those afflicted, as well ...